Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo Controlled Study Assessing the Efficacy and Safety of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder

NCT00285376 is registered in ClinicalTrials.gov with Genaissance Pharmaceuticals as lead sponsor.

NCT NCT00285376
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00285376 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Efficacy and Safety of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder
Lead sponsor
Genaissance Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2006
Completion date
May 31, 2007
Enrollment
410 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major